Science advances · 2020
Development of a potent Zika virus vaccine using self-amplifying messenger RNA.
СтатьяResearch Support, N.I.H., IntramuralПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Luisi Kate, Morabito Kaitlyn M, Burgomaster Katherine E, Sharma Mayuri, Kong Wing-Pui, Foreman Bryant M, Patel Sonal, Fisher Brian, Aleshnick Maya A, Laliberte Jason, Wallace Madison, Ruckwardt Tracy J, Gordon David N, Linton Christine, Ruggiero Nicole, Cohen Jessica L, Johnson Russell, Aggarwal Kunal, Ko Sung-Youl, Yang Eun Sung, Pelc Rebecca S, Dowd Kimberly A, O'Hagan Derek, Ulmer Jeffrey, Mossman Sally, Sambor Anna, Lepine Edith, Mascola John R, Pierson Theodore C, Graham Barney S, Yu Dong
Аннотация
Zika virus (ZIKV) is the cause of a pandemic associated with microcephaly in newborns and Guillain-Barre syndrome in adults. Currently, there are no available treatments or vaccines for ZIKV, and the development of a safe and effective vaccine is a high priority for many global health organizations. We describe the development of ZIKV vaccine candidates using the self-amplifying messenger RNA (SAM) platform technology delivered by cationic nanoemulsion (CNE) that allows bedside mixing and is particularly useful for rapid responses to pandemic outbreaks. Two immunizations of either of the two lead SAM (CNE) vaccine candidates elicited potent neutralizing antibody responses to ZIKV in mice and nonhuman primates. Both SAM (CNE) vaccines protected these animals from ZIKV challenge, with one candidate providing complete protection against ZIKV infection in nonhuman primates. The data provide a preclinical proof of concept that a SAM (CNE) vaccine candidate can rapidly elicit protective immunity against ZIKV.